To investigate the effectiveness of multicomponent integrated care on clinical outcomes
among patients with chronic heart failure. We conducted a meta‐analysis of randomized …

Background: Empagliflozin is the first medication to demonstrate clinical benefit in patients
with heart failure with preserved ejection fraction, but its cost-effectiveness is unknown. We …

Aim To assess the cost-effectiveness of dapagliflozin in addition to standard care versus
standard care alone in patients with chronic heart failure and reduced ejection fraction …

Aims To examine sex-stratified differences in the association of left ventricular ejection
fraction-based heart failure (HF) subtypes and the characteristics and correlates of self …

Advanced chronic kidney disease (CKD) frequently aggravates heart failure (HF). However,
these patients have inherently been excluded from most HF trials. We aim to provide …

Aims We aimed to recruit a representative cohort of women and men with multi-morbid
chronic heart disease as part of a trial testing an innovative, nurse-co-ordinated, multi …

Background Frailty is an important predictive measure of mortality and rehospitalisation in
people with heart failure. To date, there are no frailty instruments validated for use in people …

Objective Recent studies have reported suboptimal up-titration of heart failure (HF) therapies
in patients with heart failure and a reduced ejection fraction (HFrEF). Here, we report on the …

Background The New South Wales (NSW) Heart Failure Snapshot sought to provide a
contemporaneous profile of patients admitted with acute heart failure. We have previously …

For patients with heart failure (HF), the transition period from hospital to home remains a
critical period of vulnerability. Transitional and community-based interventions aimed at …